Erdosteine for COPD inflammation
Part of Lungs & breathing clinical trials.
This study tests whether a medicine called erdosteine can help reduce inflammation in people with stable COPD. If you are 45 or older and have had COPD for at least a year without recent flare-ups, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years or older.
- You have had COPD for at least 1 year.
- You have been stable (no flare-ups, infections, or hospital stays) in the last 3 months.
- Your lung function test shows moderate to severe airflow blockage (FEV1 between 30% and 80% of predicted).
- You take inhaled COPD medications (LAMA/LABA or LAMA/LABA/ICS) and have not changed doses in the last 3 months.
- You do not have severe heart failure, unstable heart rhythm, active cancer, or a known allergy to erdosteine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how inflammation and oxidative stress affect COPD. It tests whether a pulmonary rehabilitation program helps reduce these factors in people with stable COPD who are former smokers.
This trial tests whether inhaled corticosteroids (steroid inhalers) help people with mild-to-moderate COPD breathe better in areas with higher air pollution. You may join if you have mild-to-moderate COPD, are between 40 and 80, and haven't smoked for at least six months.
This trial tests a structured review process to help people with COPD who have needed multiple steroid pills in the past year. It aims to improve care and prevent future harm from the condition.
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This trial tests whether adding doxofylline to your usual inhalers can improve lung function and breathing tests in people with stable COPD. It may help if your COPD is moderate to worse and you have been stable for at least 6 months.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.